Key Points
- Director Rosty Raykov sold 10,946 shares at an average $6.31 (≈$69,069) on April 1 under a pre‑arranged Rule 10b5‑1 plan, trimming his stake by 8.77% to 113,856 shares valued at about $718,431.
- Adherex reported quarterly EPS of -$0.17 vs. an estimate of $0.04 and missed revenue expectations, leaving the company with negative margins and ROE and prompting near‑term analyst cuts.
- Analysts are mixed but the consensus is a "Moderate Buy" with a $15.25 target, and institutional investor AQR took a new ~10,897‑share position (~$66k), indicating some institutional interest.
Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,946 shares of Adherex Technologies stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $6.31, for a total value of $69,069.26. Following the sale, the director directly owned 113,856 shares in the company, valued at $718,431.36. The trade was a 8.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Rosty Raykov also recently made the following trade(s):
- On Monday, February 2nd, Rosty Raykov sold 10,349 shares of Adherex Technologies stock. The shares were sold at an average price of $7.76, for a total value of $80,308.24.
Adherex Technologies Trading Up 0.2%
Shares of FENC opened at $6.42 on Friday. The stock has a market cap of $221.30 million, a PE ratio of -18.88 and a beta of 0.93. Adherex Technologies Inc. has a 1 year low of $4.68 and a 1 year high of $9.92. The stock has a 50 day simple moving average of $7.72 and a 200-day simple moving average of $8.01.
Adherex Technologies (NASDAQ:FENC - Get Free Report) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.21). Adherex Technologies had a negative net margin of 22.62% and a negative return on equity of 183.18%. The company had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.75 million. On average, sell-side analysts forecast that Adherex Technologies Inc. will post -0.11 EPS for the current fiscal year.
Key Stories Impacting Adherex Technologies
Here are the key news stories impacting Adherex Technologies this week:
- Positive Sentiment: HC Wainwright is projecting positive earnings in 2027 (Q1 2027 ~$0.17, Q2 2027 ~$0.22) and raised forward-period estimates that imply recovery after current-year weakness — a bullish signal for longer‑term upside. HC Wainwright estimates / MarketBeat
- Positive Sentiment: Analysts' consensus recommendation of "Moderate Buy" provides institutional validation and can support buying interest. Consensus Moderate Buy
- Neutral Sentiment: Director Rosty Raykov sold 10,946 shares at an average $6.31 (≈$69k), reducing his stake by 8.77%. The sale was executed under a pre‑arranged Rule 10b5‑1 plan, which typically reduces the informational significance of the trade. SEC Form 4
- Negative Sentiment: HC Wainwright trimmed near‑term and FY2026 forecasts sharply (e.g., FY2026 cut from $0.64 to $0.31; Q1 2026 cut to ($0.02) from $0.07; Q2 2026 cut to $0.05 from $0.14). Reduced near‑term earnings expectations are a clear headwind for the stock. HC Wainwright outlook
- Negative Sentiment: Recent quarterly results showed a miss (last reported EPS -$0.17 vs. est. $0.04; revenue below estimates), leaving the company operating with negative margins and a negative ROE — background weakness that amplifies sensitivity to analyst cuts. Recent results / MarketBeat
Institutional Trading of Adherex Technologies
An institutional investor recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC purchased a new stake in Adherex Technologies Inc. (NASDAQ:FENC - Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,897 shares of the company's stock, valued at approximately $66,000. 55.51% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on FENC shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adherex Technologies in a report on Thursday, January 22nd. Piper Sandler assumed coverage on shares of Adherex Technologies in a research report on Friday, January 9th. They issued an "overweight" rating and a $18.00 price target on the stock. B. Riley Financial assumed coverage on shares of Adherex Technologies in a research note on Thursday, February 12th. They set a "buy" rating and a $16.00 price objective on the stock. Wall Street Zen lowered shares of Adherex Technologies from a "strong-buy" rating to a "buy" rating in a report on Saturday, March 14th. Finally, Zacks Research cut shares of Adherex Technologies from a "hold" rating to a "strong sell" rating in a research note on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.25.
Read Our Latest Analysis on FENC
Adherex Technologies Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
